{"id":757278,"date":"2023-05-10T08:38:27","date_gmt":"2023-05-10T12:38:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/"},"modified":"2023-05-10T08:38:27","modified_gmt":"2023-05-10T12:38:27","slug":"pliant-therapeutics-to-participate-in-upcoming-investor-events-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/","title":{"rendered":"Pliant Therapeutics to Participate in Upcoming Investor Events"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., May  10, 2023  (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following May investor events.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Piper Sandler PSC\/PBC Symposium<\/strong> Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer and \u00c9ric Lefebvre, M.D., Pliant\u2019s Chief Medical Officer, will participate in a fireside chat on Friday, May 12, 2023, to discuss the Company\u2019s primary sclerosing cholangitis (PSC) program. This is an invitation-only event hosted by Piper Sandler.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>2023 RBC Capital Markets Global Healthcare Conference <\/strong>Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer and \u00c9ric Lefebvre, M.D., Pliant\u2019s Chief Medical Officer, will participate in a fireside chat on Wednesday, May 17, 2023, at 1:35 p.m. Eastern Time.<\/li>\n<li style=\"margin-top:10pt;margin-bottom:8pt\">\n          <strong>Stifel West Coast Bus Tour <\/strong>Members of Pliant\u2019s senior management will meet with investors on Wednesday, May 24, 2023, as part of an invitation-only event hosted by Stifel.<\/li>\n<\/ul>\n<p>Interested parties may access the live webcast of the RBC fireside chat by visiting the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NCqGX2jVMbJcas2Gzp1AUXexKvYeYw8oOe3Uqo5OaXhEJaN0haMcUTCq0NNv1CoEkP-ZjfvMUF6MU6Quj2MrxUEuLECUxiVngFa9hqcSh91LBUHxsq_VtTSMsVniHlFuTZlHfyZFGZ6l5EBayOC74cwYzQ2urwK3IbtyHZ-_xp8=\" rel=\"nofollow noopener\" target=\"_blank\">Investor Relations\u2019 Events &amp; Presentation<\/a> page of Pliant\u2019s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event.<\/p>\n<p>\n        <strong>About\u00a0Pliant Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant&#8217;s lead product candidate, bexotegrast, is an oral small molecule dual selective inhibitor of \u03b1v\u00df6 and \u03b1v\u00df1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant is currently conducting a Phase 2a trial of bexotegrast in the PSC and is planning a Phase 2b trial in IPF. Pliant has also developed PLN-1474, a small molecule selective inhibitor of \u03b1v\u00df1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis. In December 2022, Pliant submitted an IND for its third clinical program, PLN-101095, a small molecule dual-selective inhibitor of \u03b1v\u03b28 and \u03b1v\u03b21 integrins, that is being developed for the treatment of solid tumors. In addition to clinical stage programs, Pliant currently has a preclinical program targeting muscular dystrophies. For additional information about Pliant Therapeutics, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-PRsd5rBg5T7W0e62McMXhsE04zZF2-3BFIUNbAubOaet0LrR1nl3SKJZ2NbBhQImEsBOeZlOYqeSQ_eHsI_Iw==\" rel=\"nofollow noopener\" target=\"_blank\">www.pliantrx.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G9lGS2jTRbbWwG-FbyAf8Stbu9rwbiZNr0zlTZwBdaDO3ksIXPEoVa4diNr8SELa-K98ooHP4cnX20qjrrEtZw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XICOMx_pLXs0H79aEV-tRVoFMN7yDs0jHxs4UMIgFCTpP6mMplb2yoWSmpmkcgis8V7yWynhLicN4vtPYm-PrJ8PqZ2Y8Z8QUtEg3Uho6wE=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1mdUUEtnVoCp_lhdIQu11qGthD3Rwf6sz0nBHO63C9gSqLY2pYcdx3EFmwalHtbp2ZR7-_TLrW9SfhJUOGGFDg==\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uGUjoeKW-5ZlRbhN-FFVpqYjON4XJz9s3Ujy_69XPDKg1dFtHtisrlZKFvF41x6gIMP9z6cWN-aWcLdmTJmN4CDtA5_JUrAnbqZUxkbqyLJA3e2yJKIS5Tron0asEvDF\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p>\n        <strong>Investor and Media Contact:<\/strong>\n      <\/p>\n<p>Christopher Keenan<br \/>Vice President, Investor Relations and Corporate Communications<br \/>Pliant Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qN6O1OAsAIyvTzjFGYyzWtI6RYesVuo-vaE2raoAlSIrWdnngEYIs9b-eAlSOmzv1qvKddWG8dDzk69ipfrUJA==\" rel=\"nofollow noopener\" target=\"_blank\">ir@pliantrx.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NGQ4ZjczNGMtOTllOC00MzdkLTlhNzItMjIwYTZjMzU5YzY0LTExOTcwMzA=\/tiny\/Pliant-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following May investor events. Piper Sandler PSC\/PBC Symposium Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer and \u00c9ric Lefebvre, M.D., Pliant\u2019s Chief Medical Officer, will participate in a fireside chat on Friday, May 12, 2023, to discuss the Company\u2019s primary sclerosing cholangitis (PSC) program. This is an invitation-only event hosted by Piper Sandler. 2023 RBC Capital Markets Global Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer and \u00c9ric Lefebvre, M.D., Pliant\u2019s Chief Medical Officer, will participate in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pliant Therapeutics to Participate in Upcoming Investor Events&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-757278","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pliant Therapeutics to Participate in Upcoming Investor Events - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics to Participate in Upcoming Investor Events - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following May investor events. Piper Sandler PSC\/PBC Symposium Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer and \u00c9ric Lefebvre, M.D., Pliant\u2019s Chief Medical Officer, will participate in a fireside chat on Friday, May 12, 2023, to discuss the Company\u2019s primary sclerosing cholangitis (PSC) program. This is an invitation-only event hosted by Piper Sandler. 2023 RBC Capital Markets Global Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer and \u00c9ric Lefebvre, M.D., Pliant\u2019s Chief Medical Officer, will participate in &hellip; Continue reading &quot;Pliant Therapeutics to Participate in Upcoming Investor Events&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-10T12:38:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics to Participate in Upcoming Investor Events\",\"datePublished\":\"2023-05-10T12:38:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/\"},\"wordCount\":444,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/\",\"name\":\"Pliant Therapeutics to Participate in Upcoming Investor Events - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY=\",\"datePublished\":\"2023-05-10T12:38:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics to Participate in Upcoming Investor Events\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics to Participate in Upcoming Investor Events - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics to Participate in Upcoming Investor Events - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following May investor events. Piper Sandler PSC\/PBC Symposium Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer and \u00c9ric Lefebvre, M.D., Pliant\u2019s Chief Medical Officer, will participate in a fireside chat on Friday, May 12, 2023, to discuss the Company\u2019s primary sclerosing cholangitis (PSC) program. This is an invitation-only event hosted by Piper Sandler. 2023 RBC Capital Markets Global Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer and \u00c9ric Lefebvre, M.D., Pliant\u2019s Chief Medical Officer, will participate in &hellip; Continue reading \"Pliant Therapeutics to Participate in Upcoming Investor Events\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-10T12:38:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics to Participate in Upcoming Investor Events","datePublished":"2023-05-10T12:38:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/"},"wordCount":444,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/","name":"Pliant Therapeutics to Participate in Upcoming Investor Events - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY=","datePublished":"2023-05-10T12:38:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTc3OCM1NTg1NjY3IzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-upcoming-investor-events-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics to Participate in Upcoming Investor Events"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/757278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=757278"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/757278\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=757278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=757278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=757278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}